LifeStance Health Group, Inc. (NASDAQ:LFST – Get Rating) – Stock analysts at William Blair upped their Q3 2022 EPS estimates for LifeStance Health Group in a research note issued on Monday, May 9th. William Blair analyst R. Daniels now forecasts that the company will post earnings of ($0.15) per share for the quarter, up from their prior estimate of ($0.16). William Blair also issued estimates for LifeStance Health Group’s Q4 2022 earnings at ($0.14) EPS, FY2022 earnings at ($0.64) EPS and FY2023 earnings at ($0.21) EPS.
Several other equities analysts have also commented on LFST. UBS Group lowered LifeStance Health Group from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $19.00 to $10.00 in a research report on Thursday, March 17th. Zacks Investment Research raised LifeStance Health Group from a “sell” rating to a “hold” rating in a research report on Thursday. Finally, The Goldman Sachs Group reduced their price target on LifeStance Health Group from $15.00 to $10.00 and set a “neutral” rating on the stock in a research report on Monday, March 21st. Five equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, LifeStance Health Group presently has a consensus rating of “Hold” and a consensus price target of $16.00.
LifeStance Health Group (NASDAQ:LFST – Get Rating) last released its quarterly earnings data on Monday, May 9th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.03). The firm had revenue of $203.10 million during the quarter, compared to analyst estimates of $191.47 million. LifeStance Health Group had a negative net margin of 46.02% and a negative return on equity of 20.93%. The firm’s quarterly revenue was up 41.9% on a year-over-year basis.
Several hedge funds and other institutional investors have recently modified their holdings of LFST. BlackRock Inc. grew its stake in LifeStance Health Group by 130.4% during the 3rd quarter. BlackRock Inc. now owns 4,607,687 shares of the company’s stock worth $66,811,000 after buying an additional 2,607,735 shares during the last quarter. Norges Bank bought a new position in LifeStance Health Group during the 4th quarter worth $12,583,000. Janus Henderson Group PLC grew its stake in LifeStance Health Group by 42.5% during the 3rd quarter. Janus Henderson Group PLC now owns 3,734,508 shares of the company’s stock worth $54,150,000 after buying an additional 1,114,037 shares during the last quarter. Geode Capital Management LLC grew its stake in LifeStance Health Group by 253.1% during the 3rd quarter. Geode Capital Management LLC now owns 975,652 shares of the company’s stock worth $14,146,000 after buying an additional 699,377 shares during the last quarter. Finally, Integral Health Asset Management LLC bought a new position in LifeStance Health Group during the 3rd quarter worth $5,075,000. Institutional investors and hedge funds own 80.71% of the company’s stock.
In other news, insider Kevin Michael Mullins sold 46,283 shares of the business’s stock in a transaction that occurred on Wednesday, April 20th. The stock was sold at an average price of $10.68, for a total value of $494,302.44. Following the completion of the sale, the insider now directly owns 5,669,472 shares in the company, valued at approximately $60,549,960.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Jesse Michael Bruff sold 18,401 shares of the business’s stock in a transaction that occurred on Monday, March 14th. The shares were sold at an average price of $7.92, for a total value of $145,735.92. The disclosure for this sale can be found here.
About LifeStance Health Group (Get Rating)
LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.
- Get a free copy of the StockNews.com research report on LifeStance Health Group (LFST)
- Corning Stock is a Technology Value Play
- Anheuser-Busch InBev May Need One More Quarter to Confirm a Buy Signal
- Wolverine Worldwide Is Ready To Rebound
- Wendy’s Growth Story Has Come To An End
- Beyond Meat Could Sizzle After Q1 Results Are Released
Receive News & Ratings for LifeStance Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeStance Health Group and related companies with MarketBeat.com's FREE daily email newsletter.